A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line results ...

In the 557-patient study, Enhertu reduced the risk of disease progression or death by 50%, whilst improving overall survival by 36% compared to chemotherapy – translating to an extra half year ...

Join our webinar on 11/20 with author and business coach Darcy Juarez to learn simple, budget-friendly marketing strategies that will attract clients and grow your business fast. Register now!

Enhertu is already approved or has accelerated approval for the treatment of several cancers involving HER mutations, including breast cancer, non-small cell lung cancer, gastroesophageal junction ...

Join a free webinar – live or on demand – to hear from leading medical experts on a variety of health conditions and topics. WebMD has teamed with specialty physicians and researchers who ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

The safety profile of Enhertu was similar to that seen in previous studies for breast cancer indications. Enhertu — A Key Oncology Drug for AZN Enhertu, a specifically engineered HER2-directed ...

to develop and commercialize a subcutaneous version of ENHERTU ® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate (ADC) that has been jointly developed and ...

Daiichi Sankyo (TSE:4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have been awarded The Galien Foundation 2024 Prix Galien USA Award for Best Biotechnology Product for ENHERTU® (fam-trastuzumab ...

Trodelvy shows consistent efficacy in metastatic triple-negative breast cancer with a 27.8% ORR and 4.8 months PFS. Enhertu demonstrates promising results in HER2-low patients post-Trodelvy, achieving ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.